Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16736605 | 0.84 | TYR (0.46) | MAPTTHRBTYRTP53CYP2C9 | |
| SCHEMBL23811946 | 0.82 | TP53 (0.32) | CTRCMAPTTHRBTYRTP53 | |
| SCHEMBL8359245 | 0.75 | CTRC (0.44) | CTRCMAPTTYRTP53HIF1A | |
| SCHEMBL14850392 | 0.75 | KCNH2 (0.41) | MAPTTYRTP53SMN1; SMN2 | |
| SCHEMBL30604741 | 0.74 | ALOX15 (0.56) | MAPTTHRBTYRTP53CYP2C9 | |
| SCHEMBL28861133 | 0.74 | TYR (0.38) | MAPTTHRBTYRTP53CYP2C9 | |
| SCHEMBL3408192 | 0.74 | ALOX15 (0.56) | MAPTTHRBTYRTP53CYP2C9 | |
| SCHEMBL16736743 | 0.74 | ALOX15 (0.45) | MAPTTYRTP53CYP2C9CYP2C19 | |
| SCHEMBL16736854 | 0.73 | HMGCR (0.44) | MAPTTYRTP53CYP2C9CYP2C19 | |
| SCHEMBL29003638 | 0.73 | TYR (0.58) | MAPTTYRTP53CYP2C9HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-10952978-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952978-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | CTRC 2404/4885MAPT 4660/4885THRB 2632/4885 |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | CTRC 2404/4885MAPT 4660/4885THRB 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.